Peptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
Peptide names are not interchangeable labels. A research name, vendor acronym, salt form, fragment, pegylated variant, or multi-peptide blend can each represent a different product with different evidence and regulatory status. "CJC-1295," "TB-500," and "GHK-Cu" are examples where public discussion merges distinct chemical entities.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- Cochrane: What are systematic reviews?
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
5-Amino-1MQ
When a laboratory value changes but patient outcomes remain uncertain.
Open resourcePeptide brief5-Amino-1MQ / SLU-PP-332
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefAlpha-Klotho mAb
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefAOD-9604
A framework for evaluating evidence and regulatory claims around an hGH-fragment research compound.
Open resourcePeptide briefARA-290
An overview of erythropoietin-derived peptide research without turning orphan-drug development into a wellness claim.
Open resourcePeptide briefATX-304
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceArticleHow to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resource